Underrepresentation of female subjects in BE study to register Generic [Regulatives / Guidelines]

posted by ping4santosh  – India, 2020-03-11 14:35 (403 d 07:39 ago) – Posting: # 21247
Views: 5,885

Dear All,

I request your help to arrive at a decision on male to female ratio in a BE trial. We have done a pilot study with 12 subjects (8 male and 4 female) and the results didn't meet the bioequivalence criteria. However, when we exclude the female data it marginally meets the bioequivalency crtieria of 80%-125%.

Can we conduct the pivotal study only in Males? Can we extrapolate the conclusions obtained in males to females. What would be the regulatory challenges and please prove some references that can guide me on this.

Thanks a lot for your support.
Best wishes,

Complete thread:

 Admin contact
21,419 posts in 4,475 threads, 1,508 registered users;
online 8 (0 registered, 8 guests [including 1 identified bots]).
Forum time: Sunday 23:14 CEST (Europe/Vienna)

Nothing fails like success because you do not learn anything from it.
The only thing we ever learn from is failure.
Success only confirms our superstitions.    Kenneth E. Boulding

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz